Regorafenib impurity 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-hydroxyphenyl)urea is an impurity generated during the manufacturing process of regorafenib; regorafenib is a novel multikinase inhibitor developed by Bayer that inhibits multiple protein kinases involved in tumor growth, angiogenesis, and maintenance of tumor microenvironment signaling.